AlphAIAlphAI — Financial news for AI agents
investing.comOCT 132 min read$PHIO

Phio Pharmaceuticals completes first commercial-scale PH-762 batch

Phio Pharmaceuticals (PHIO) announced the completion of its first commercial-scale batch of PH-762 drug substance, meeting regulatory and quality standards. The batch will be used in a planned Phase 2b clinical study expected to begin in Q1 2027. PH-762 targets the PD-1 gene in skin cancers.

Original reporting
investing.com
Published Oct 13, 2026, 11:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 11:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$PHIO
Bullish
high confidence
Mentioned
$PHIO
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PHIOBullishMed
01

Why it matters

The commercial‑scale batch validates the manufacturing process, a key de‑risking step before pivotal trials.

02

Market read

First batch release is a material corporate milestone that may lift PHIO ahead of its Phase 2b trial.

03

What to watch

Potential manufacturing scale‑up challenges or regulatory scrutiny of cGMP compliance could delay trial start.

Relevance 7/10Novelty 8/10Timing: Phase 2b trial slated for Q1 2027

Background

Phio Pharmaceuticals develops cancer therapeutics using its INTASYL siRNA platform; PH‑762 targets PD‑1 for skin cancers.

Company-level read

Ticker impact

$PHIOBullishHigh confidence
Context

Phio Pharmaceuticals announced the release of its first commercial‑scale cGMP batch of PH‑762, enabling the start of a Phase 2b trial in Q1 2027.

Expected impact

likely upward pressure as investors price in the upcoming Phase 2b trial start

Evidence & confidence

First commercial‑scale batch is a material milestone for a clinical‑stage biotech; market typically reacts positively to de‑risking manufacturing steps.

Market effects

Sector

Shows progress in siRNA therapeutics, may boost sentiment for other RNA‑based biotech peers.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

If the Phase 2b data disappoint, the batch milestone could be priced in already, limiting upside.

Key entities

  • company
    Phio Pharmaceuticals Corp.

    Clinical‑stage biotech developing siRNA cancer drugs.

  • executive
    Robert Bitterman

    President and CEO of Phio Pharmaceuticals.

Read at source← All news

StoryPhio Pharmaceuticals completes first commercial‑scale cGMP batch of PH‑762, enabling Phase 2b start in early 2027

Also covered by

1 outlet

Related articles

OCT 13
$PHIOMedAI 8/10

A cancer drug's first production-scale batch is complete; a clinical study is planned for early 2027.

Phio Pharmaceuticals (PHIO) announced the successful production of its first commercial-scale batch of PH-762, a cancer drug. The batch meets quality standards and will be used in a planned Phase 2b clinical trial set to begin in Q1 2027. The company's CEO highlighted this as a significant milestone, reducing development risks and supporting future clinical and regulatory steps.

stocktitan.net2 min
SEP 14
$PHIOMedAI 8/10

Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma

Phio Pharmaceuticals (PHIO) submitted a meeting request and briefing package to the FDA for PH-762, its lead clinical compound for cutaneous squamous cell carcinoma. The submission follows the completion of a Phase 1b trial and outlines plans for a Phase 2b study. The company expects to complete final activities for the next clinical phase by Q1 2027.

insidermonkey.com2 min
SEP 14
$PHIOMedAI 8/10

Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma

Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma Company Proposes Planned Phase 2b Neoadjuvant Study Following Successful Completion of Phase 1b Trial KING OF PR

SEC EDGAR 8-K1 min
AUG 6
$PHIOMedAI 8/10

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Phio Pharmaceuticals (NASDAQ: PHIO) reported Q2 2026 results for the quarter ended June 30, 2026 and updated its PH-762 siRNA program. Cash fell to $13.0M from $21.0M at Dec. 31, 2025. R&D rose to $3.1M and net loss widened to $4.1M. PH-762 Phase 1b (22 patients) completed in March; FDA documentation is being prepared and an FDA meeting is planned for Q3 2026. The company also launched a $6.36M ATM equity program.

finanznachrichten.de7 min
AUG 6
$PHIOMed

Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update Strategic milestone advancements for lead clinical candidate PH-762

Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase 1b pharmacology, and

SEC EDGAR 8-K6 min